Chronische Lymphatische Leukämie

Zusammenfassung

Die chronische lymphatische Leukämie ist eine Erkrankung mit sehr heterogenem Verlauf. Mithilfe verschiedener Faktoren können Abschätzungen bezüglich des Krankheitsverlaufs erfolgen und individualisierte Therapien angewandt werden. Zielgerichtete Therapien, die sich gegen das B-Zell-Rezeptor-Signalling oder das anti-apoptotische Protein BCL-2 richten, bieten die Möglichkeit einer chemotherapie-freien Behandlung. Diese Therapien zeigen bei quasi allen Patienten, insbesondere auch nach intensiver Vortherapie und bei Hochrisikogenetik, ein gutes Ansprechen und lange Überlebenszeiten.

• Literatur

• 1 Hallek M, Cheson BD, Catovsky D. et al. iwCLL Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood 2018; 131: 2745-2760
• 2 Hamblin TJ, Davis Z, Gardiner A. et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854
• 3 Eichhorst B, Robak T, Montserrat E. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v78-v84
• 4 Döhner H, Stilgenbauer S, Benner A. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916
• 5 Hallek M, Fischer K, Fingerle-Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174
• 6 Landau DA, Tausch E, Taylor-Weiner AN. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525-530
• 7 Fabbri G, Rasi S, Rossi D. et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401
• 8 Wendtner C-M, Dreger P, Gregor M. et al. Chronische Lymphatische Leukämie (CLL). Leitlinie. 11/2014 https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@view/html/index.html Accessed Juli 2018
• 9 Dreger P, Ghia P, Schetelig J. et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies. Blood. 2018 blood-2018–01–826008
• 10 Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018 blood-2018–01–785998
• 11 O’Brien S, Furman RR, Coutre SE. et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014; 15: 48-58
• 12 Stilgenbauer S, Eichhorst B, Schetelig J. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17: 768-778
• 13 Eichhorst B, Fink A-M, Bahlo J. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928-942
• 14 Goede V, Fischer K, Busch R. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110
• 15 Burger JA, Tedeschi A, Barr PM. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373: 2425-2437
• 16 O’Brien S, Jones JA, Coutre SE. et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016; 17: 1409-1418
• 17 Souers AJ, Leverson JD, Boghaert ER. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202
• 18 Seymour JF. Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia. Ann Hematol 2016; 95: 1361
• 19 Stilgenbauer S, Eichhorst B, Schetelig J. et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 JCO. 2017.76. 6840
• 20 Furman RR, Sharman JP, Coutre SE. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007
• 21 Seymour JF, Kipps TJ, Eichhorst B. et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; 378: 1107-1120
• 22 Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018 blood-2018–01–791376